PIN53 COST EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN (RBV) FOR RE-TREATMENT OF HCV GENOTYPE I (Gl) PATIENTS WHO DID NOT RESPOND TO PREVIOUS HCV TREATMENT- A UK PERSPECTIVE

Oct 1, 2009, 00:00 AM
10.1016/S1098-3015(10)75111-1
https://www.valueinhealthjournal.com/article/S1098-3015(10)75111-1/fulltext
Section Title :
Section Order : 1036
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)75111-1&doi=10.1016/S1098-3015(10)75111-1
HEOR Topics :
Tags :
Regions :